drugset / Trial / NCT00220649

Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

NCT00220649

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.

Timeline

Start
2004-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule
Background Gemcitabine Small molecule
Background Irinotecan Small molecule
Background Leucovorin Small molecule
Background fluorouracil Small molecule

Indications